Advertisement
Advertisement
DNA
Ginkgo Bioworks Holdings, Inc.
7.97
USDSponsored
-0.53
-6.24%
Aug 07, 15:59 UTC -4
Closed
After-Market
7.87
-0.10
-1.25%
DNA Earnings Reports
Positive Surprise Ratio
DNA beat 7 of 19 last estimates.
37%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Ginkgo Bioworks Holdings, Inc. earnings per share and revenue
On May 07, 2026, DNA reported earnings of -1.39 USD per share (EPS) for Q1 26, missing the estimate of -1.09 USD, resulting in a -27.43% surprise. Revenue reached 25.68 million, compared to an expected 41.94 million, with a -38.75% difference. The market reacted with a -13.47% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Ginkgo Bioworks Holdings, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Ginkgo Bioworks Holdings, Inc. reported EPS of -$1.39, missing estimates by -27.43%, and revenue of $25.68M, -38.75% below expectations.
How did the market react to Ginkgo Bioworks Holdings, Inc.'s Q1 2026 earnings?
The stock price moved down -13.47%, changed from $10.32 before the earnings release to $8.93 the day after.
When is Ginkgo Bioworks Holdings, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Ginkgo Bioworks Holdings, Inc.'s next earnings report?
Based on --
analysts, Ginkgo Bioworks Holdings, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement